Dafna Capital Management LLC Ardelyx, Inc. Transaction History

Dafna Capital Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$5.05 - $7.1 $730,482 - $1.03 Million	-144,650 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$5.25 - $7.08 $211,050 - $284,616	-40,200 Reduced 21.75%	144,650 $759,000
Q1 2020 May 15, 2020	SELL	$4.35 - $8.79 $65,249 - $131,850	-15,000 Reduced 7.51%	184,850 $1.05 Million
Q4 2019 Feb 14, 2020	SELL	$4.23 - $8.29 $1.61 Million - $3.16 Million	-380,674 Reduced 65.57%	199,850 $1.5 Million
Q3 2019 Nov 14, 2019	SELL	$2.15 - $6.28 $217,655 - $635,755	-101,235 Reduced 14.85%	580,524 $2.73 Million
Q2 2019 Aug 14, 2019	BUY	$2.49 - $3.73 $12,450 - $18,650	5,000 Added 0.74%	681,759 $1.83 Million
Q1 2019 May 15, 2019	BUY	$1.88 - $3.35 $383,332 - $683,065	203,900 Added 43.12%	676,759 $1.9 Million
Q2 2018 Aug 13, 2018	BUY	$3.7 - $5.8 $832,500 - $1.31 Million	225,000 Added 90.78%	472,859 $1.75 Million
Q1 2018 May 15, 2018	SELL	$5.05 - $7.9 $137,360 - $214,880	-27,200 Reduced 9.89%	247,859 $1.25 Million
Q4 2017 Feb 14, 2018	SELL	$4.85 - $7.8 $244,197 - $392,730	-50,350 Reduced 15.47%	275,059 $1.82 Million
Q3 2017 Nov 14, 2017	BUY	$4.35 - $5.7 $1.42 Million - $1.85 Million	325,409	325,409 $1.82 Million

218

141M

1.08M

Ticker ARDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 154,636,000
Market Cap $799M
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...

Get notified when there are updates to the investment portfolio of Dafna Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Dafna Capital Management LLC with notifications on news.